A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Malignant Peritoneal Mesothelioma|Peritoneal Mesothelioma|Mesothelioma|Mesothelioma, Malignant|Malignant Mesothelioma
DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Carboplatin
Progression Free Survival, Progression Free Survival in the two treatment arms., up to 24 months
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.